Renaissance Technologies LLC Has $1.71 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Renaissance Technologies LLC cut its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,900 shares of the company's stock after selling 3,500 shares during the period. Renaissance Technologies LLC's holdings in Krystal Biotech were worth $1,708,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. FMR LLC grew its stake in Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after buying an additional 28,707 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after acquiring an additional 62,178 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock valued at $38,095,000 after acquiring an additional 2,954 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Krystal Biotech during the 4th quarter valued at approximately $34,391,000. 86.29% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, HC Wainwright raised their price target on Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a report on Monday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $222.71.

Krystal Biotech Stock Up 0.6 %

KRYS traded up $1.05 during trading on Friday, reaching $166.74. The stock had a trading volume of 35,754 shares, compared to its average volume of 294,172. The stock has a 50 day moving average of $175.22 and a two-hundred day moving average of $171.38. The firm has a market capitalization of $4.82 billion, a price-to-earnings ratio of 55.68 and a beta of 0.75. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company's revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.30 earnings per share. On average, research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).